Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of SQ-24071 eye drops, which are intended to slow the progression of myopia in children and adolescents [1] Group 1 - SQ-24071 eye drops are classified as a modified new drug of chemical drugs category 2.2 and 2.4 [1] - The company has completed various studies on SQ-24071, including pharmaceutical and non-clinical pharmacology and toxicology, demonstrating good safety and clinical development value [1] - There are currently no similar eye drop formulations available in the domestic and international markets [1]

Core Viewpoint - The company, Xingqi Eye Medicine, has received approval from the National Medical Products Administration for clinical trials of SQ-24071 eye drops, aimed at delaying the progression of myopia in children and adolescents [1] Company Summary - Xingqi Eye Medicine announced on January 19 that it has obtained a clinical trial approval notice for SQ-24071 eye drops from the National Medical Products Administration [1]

Group 1 - The core point of the article is that Xingqi Eye Pharmaceutical (300573) has received approval from the National Medical Products Administration for the clinical trial of SQ-24071 eye drops, which are intended to slow the progression of myopia in children and adolescents [1] - SQ-24071 is classified as a chemical drug of category 2.2; 2.4, indicating it is a modified new drug [1] - The approval signifies a potential advancement in the treatment options available for myopia, a growing concern among younger populations [1]

证券代码：300573 证券简称：兴齐眼药 公告编号：2026-002 沈阳兴齐眼药股份有限公司 申请人：沈阳兴齐眼药股份有限公司 关于SQ-24071滴眼液获得临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，沈阳兴齐眼药股份有限公司（以下简称"公司"）收到国家药品监督 管理局签发的关于 SQ-24071 滴眼液的《药物临床试验批准通知书》。现将相关情 况公告如下： 一、药品基本情况 药品名称：SQ-24071 滴眼液 适应症：拟用于延缓儿童及青少年的近视进展。 通知书编号：2026LP00170、2026LP00171、2026LP00172、2026LP00173 剂型：滴眼液 申请事项：境内生产药品注册临床试验 注册分类：化学药品 2.2；2.4 类 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 11 月 14 日受理的 SQ-24071 滴眼液符合药品注册的有关要求，同意开展临床 试验。 二、药品研发及其他情况 SQ-24071 滴眼液为我公司研发的化学药品 2.2；2.4 类改良型新药。临 ...

Group 1 - On January 16, Xingqi Eye Pharmaceutical's stock rose by 1.89% with a trading volume of 899 million yuan [1] - The financing data shows that on the same day, the company had a financing purchase amount of 137 million yuan and a financing repayment of 110 million yuan, resulting in a net financing purchase of 27.59 million yuan [1] - As of January 16, the total balance of margin trading for Xingqi Eye Pharmaceutical was 1.268 billion yuan, with a financing balance of 1.262 billion yuan, accounting for 6.54% of the circulating market value, which is above the 90th percentile level over the past year [1] Group 2 - As of September 30, the number of shareholders of Xingqi Eye Pharmaceutical reached 54,100, an increase of 16.85% compared to the previous period [2] - For the period from January to September 2025, the company achieved an operating income of 1.904 billion yuan, a year-on-year increase of 32.27%, and a net profit attributable to shareholders of 599 million yuan, a year-on-year increase of 105.98% [2] - Since its A-share listing, Xingqi Eye Pharmaceutical has distributed a total of 1.166 billion yuan in dividends, with 985 million yuan distributed over the past three years [2]

Group 1 - The company Xingqi Eye Medicine has received drug registration approval from the National Medical Products Administration for its 0.02% and 0.04% atropine sulfate eye drops on January 4, 2026 [2] - The company is currently coordinating its market promotion plan and is in the production preparation stage [2]

Group 1 - The company has received drug registration approval for its 0.02% and 0.04% atropine eye drops from the National Medical Products Administration on January 4, 2026 [2] - The company is currently coordinating its market promotion plan and is in the production preparation stage [2]

Core Viewpoint - The "Near-sightedness Prevention and Control Light-Chasing Plan" public welfare event aims to address the growing issue of myopia among children and adolescents in China, emphasizing the need for collective action and awareness in preventing and managing this condition [1][3]. Group 1: Event Overview - The event was held on January 11, 2026, in Beijing, focusing on educating families about myopia prevention through various activities such as lectures, Q&A sessions, and health consultations [1]. - The theme of the event was "1 Road Accompanying, 2 Heavy Guardianship, 4 Seasons Worry-Free," highlighting the importance of community involvement in eye health [1]. Group 2: Current Situation of Myopia - Approximately 600 million people in China are affected by myopia, with children and adolescents accounting for 50%-60% of this population, indicating a significant prevalence and severity of the condition [3]. - The National Health Commission and other departments have launched the "Five Health Promotion Action Plan" for 2026-2030, aiming to reduce the incidence of myopia through graded and classified interventions [3]. Group 3: Expert Insights - Professor Wang Ningli emphasized that myopia prevention has become a national strategy since 2018, but the overall myopia rate among children remains high, with a concerning trend of younger onset and severe cases [4]. - Recent approvals of low-concentration atropine eye drops (0.02% and 0.04%) represent significant advancements in myopia control, providing a tiered medication system for personalized treatment [4][6]. Group 4: Clinical Application and Management - The introduction of a tiered concentration system allows for dynamic adjustments in treatment based on individual responses, enhancing personalized care for children with varying degrees of myopia progression [6]. - Behavioral management, including outdoor activities and proper reading posture, remains a fundamental aspect of myopia prevention, as highlighted by experts [6]. Group 5: Public Engagement and Impact - The "Near-sightedness Prevention and Control Light-Chasing Plan" has reached tens of thousands of families nationwide, reinforcing the importance of community education in safeguarding children's vision health [6].

Core Viewpoint - The Liaoning Provincial Department of Industry and Information Technology has announced the second batch of advanced intelligent factories for 2025, with 35 enterprises selected, covering various sectors such as biomedicine, equipment manufacturing, electronic information, and new metallurgical materials. This brings the total number of advanced intelligent factories in the province to 273 [1] Group 1 - The selected enterprises include Shenyang Xingqi Eye Medicine and Dalian Zhongbi Power Battery among others [1] - The provincial government aims to implement a gradient construction action for intelligent factories, promoting the upgrade of production processes and management integration [1] - The goal for 2026 is to add over 80 advanced and above intelligent factories in the province [1] Group 2 - The initiative includes promoting basic-level intelligent factories, accelerating the transformation of production processes, and fostering collaborative management [1] - The plan also emphasizes the cultivation of excellent-level factories to drive multi-scenario intelligent applications [1] - The establishment of leading-level factories is aimed at innovating research paradigms, production methods, service systems, and organizational structures [1]

Core Insights - The provincial Industrial and Information Technology Department announced the second batch of advanced intelligent factories in Liaoning Province for 2025, with 35 enterprises selected, covering various sectors such as biomedicine, equipment manufacturing, electronic information, and new metallurgical materials [1] - A total of 273 advanced intelligent factories have been selected across the province to date [1] Group 1: Intelligent Factory Classification - Intelligent factories are categorized into four levels: basic, advanced, excellent, and leading, with the advanced level focusing on digital transformation and network collaboration [1] - The goal of advanced intelligent factories is to establish benchmarks for leading development in regional industries [1] Group 2: Case Study of Dalian Zhongbi Power Battery - Dalian Zhongbi Power Battery Co., Ltd. exemplifies the achievements of advanced intelligent factories, with its smart battery production base achieving full automation from raw materials to finished products [1] - Key processes such as winding, baking, and liquid injection have reached a 100% automation rate, and a smart central system has been established for visualizing, tracing, and optimizing the entire production process [1] - An intelligent visual system conducts online inspections of 23 critical processes, enabling "zero-distance" monitoring and precise quality control during manufacturing [1] Group 3: Future Plans for Intelligent Factories - The province aims to implement a gradient construction action for intelligent factories, promoting the upgrade of production processes and the integration of management systems [2] - There is a target to add over 80 advanced and above intelligent factories by 2026 [2]